FDA Approved: APIDRA — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for APIDRA (insulin glulisine) submitted by sanofi-aventis U.S. LLC, resulting in a labeling update for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)

Snippet

SUPPL AP for APIDRA (INSULIN GLULISINE)